menu search

Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet

Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet
In CARES 310, camrelizumab plus rivoceranib demonstrated statistically significant and clinically meaningful prolonged overall survival and progression-free survival, and improved overall response rate versus sorafenib, a standard first-line treatment for uHCC FORT LEE, N.J., July 24, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical […] The post Elevar Therapeutics Announces Publication of Phase 3 CARES 310 S... Read More
Posted: Jul 25 2023, 01:39
Author Name: forextv
Views: 092023

Search within

Pages Search Results: